-
New Hope: FDA Expands Approval for Anktiva in Bladder Cancer Treatment
NASDAQ: $IBRX A Major Milestone in Bladder Cancer Care The landscape for treating non-muscle invasive bladder cancer (NMIBC) has just seen a significant shift. The FDA has officially expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), providing a new, vital option for patients facing one of the most challenging forms of this disease. Understanding the…